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Background: Increasing evidence suggests that cancer is a metabolic disease. Here, we investigated the potential
role of fructose-1,6-bisphosphatase-2 (FBP2), the enzyme that catalyses the hydrolysis of fructose-1,6-bisphosphate
to fructose-6-phosphate and inorganic phosphate in glucose metabolism, in gastric cancer (GC) development.
Results: Our data indicated that FBP2 was downregulated in GC tissues (86.2%, 100/116), and absent or low FBP2
expression in GC tissues was correlated with poor survival of GC patients (P = 0.019). Conversely, ectopic expression
of FBP2 in GC cells activated AMP-activated protein kinase (AMPK) signalling, inhibited the Akt-mTOR pathway,
suppressed glucose metabolism, enhanced apoptosis, and reduced cell proliferation. Bisulphite genomic
sequencing (BGS) in gastric cancer cell lines revealed that the FBP2 promoter region was densely methylated, and
treatment of GC cells with the demethylation reagent, 5-aza-2-deoxycytidine (5-Aza), led to an increase in FBP2
expression. Importantly, forced expression of FBP2 abrogated tumour formation of these GC cells in nude mice.
Conclusion: Our results indicate that FBP2 does negatively regulate cell growth, and reduced expression of FBP2
may contribute to carcinogenesis for GC. These findings suggest that restoration of FBP2 expression can be a
promising strategy for the target therapy of GC.
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Gastric cancer (GC), the second most common cause of
cancer death worldwide [1], has long been thought to
result from a combination of environmental factors and
genetic alterations [2]. Activation of oncogenes and
inactivation of tumour suppressor genes have all been
implicated in gastric tumourigenesis [3,4]. However, in-
creasing evidence in recent years indicates that cancer is
a metabolic disease [5], in which cells have lost their
normal checks on cell proliferation, resulting in* Correspondence: hbzhang2006@gmail.com; youyonglu@hsc.pku.edu.cn
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reproduction in any medium, provided the orexcessive bioenergetic and biosynthetic needs [6]. To
sustain such a high demand, cancer cells must alter their
metabolism [7]. In the 1920s, Otto Warburg discovered
that cancer cells preferentially rely on glycolysis instead
of oxidative phosphorylation of glucose in normal cells
regardless of the status of oxygen supply [8,9]. As a
result, key enzymes in the glycolysis pathway are
upregulated to exert this “Warburg effect” for cancer cell
proliferation and tumourigenicity [10,11].
Fructose-1,6-bisphosphatase (FBP) is one of the key
enzymes in glucose metabolism. This enzyme catalyses
the hydrolysis of fructose-1,6-bisphosphate to fructose-
6-phosphate and inorganic phosphate and exists as two iso-
enzymes in mammals: FBP1 and FBP2. FBP1 is recognised
as the key enzyme of gluconeogenesis, and upregulated
FBP1 has been shown to suppress cancer cell growth
[12,13]; recent studies indicate that FBP2 participates in
glycogen synthesis from carbohydrate precursors [14].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sion was associated with poor clinical outcome in GC pa-
tients, while FBP2 upregulation led to inhibition of glucose
metabolism, cell proliferation and tumourigenicity. Our
findings suggested that FBP2 could be a promising bio-
marker for predicting the prognosis of GC patients and
might provide a potential target for GC therapy.
Results
Decreased FBP2 expression in primary tumours is
correlated with poor prognosis of GC patients
In our previous study, we used significance analysis of
microarrays (SAM) and Bayesian analysis of gene ex-
pression levels (BAGEL) to analyse our raw microarray
data to identify genes with altered expression in gastric
cancer [15]. Among the genes in the glucose metabolism
pathway, FBP2 was the most obviously decreased gene
in GC samples compared with adjacent and normal
tissues (Figure 1A).
To verify the decreased FBP2 expression in GC, the level
of FBP2 was determined in both GC cell lines and tissue
specimens. FBP2 mRNA was decreased in all 5 GC cell
lines (Figure 1B), and downregulation of FBP2 protein was
confirmed by Western blot analysis (Figure 1C). RT-PCR
analysis represented that decreased FBP2 expression was
detected in 88% (14/16) GC tissue specimens compared to
adjacent normal tissues (Figure 1D). In addition, immuno-
histochemistry (IHC) performed in tissue microarrays
confirmed that FBP2 protein expression was also de-
creased in GC tissues, with 86.2% (100/116) of tumour tis-
sues having low FBP2 expression and only 42.7% (47/110)
of adjacent normal tissues having low FBP2 expression
(Additional file 1: Figure S1, Table 1, P < 0.001).
Kaplan-Meier survival analysis showed that 78.8%
(41/52) of patients whose tumours exhibited low FBP2
expression had a poorer outcome than those with high
FBP2 expression (Figure 2A, Table 2, P = 0.006). More
specifically, all the samples were divided into different
stages of differentiation. For the patients with poorly
differentiated GC samples, those patients with lowly
FBP2-expressed samples had poorer outcomes than those
with highly FBP2-expressed ones (Figure 2B, P = 0.042).
Univariate analysis indicated that other factors including
tumour depth (P = 0.004), lymph node status (P = 0.006)
and distant metastasis (P = 0.020) were also associated
with poor survival (Table 2). Multivariate analysis revealed
that FBP2 expression was an independent prognostic pre-
dictor of GC (Table 3, P = 0.019) in conjunction with
tumour depth (Table 3, P = 0.012).
FBP2 inhibits cell proliferation and tumourigenicity
To investigate FBP2 function, the BGC823 cell line was
transfected with pcDNA3.1-FBP2 plasmid and used as a
cell model for both in vitro and in vivo studies.Transfection with pcDNA3.1-FBP2 plasmid resulted in
FBP2 overexpression compared with empty pcDNA3.1
plasmid (Figure 3A). The 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide (MTT) assay revealed
that FBP2 overexpression remarkably reduced cell prolif-
eration in a time-dependent manner (Figure 3B). In
addition, BGC823 cells with pcDNA3.1-FBP2 plasmid
formed fewer and smaller colonies than mock transfected
cells. More importantly, FBP2 overexpression inhibited
the growth of BGC823 xenografts. The combined results
from all the mice showed that the tumours formed by
BGC823 cells with pcDNA3.1-FBP2 plasmid were much
smaller and weighed less than those formed by mock
transfected cells (Figure 3C-D). The clonal origin of
BGC823 cells with pcDNA3.1-FBP2 plasmid in the
tumours was confirmed by staining the cells with an anti-
FBP2 antibody (Figure 3E-F).
FBP2 inhibits aerobic glycolysis through interference of
Akt-mTOR pathway
Since FBP2 plays a key role in glucose metabolism [14],
the effects of FBP2 overexpression on ATP content and
lactate concentration were examined. BGC823 cells with
pcDNA3.1-FBP2 plasmid showed decreased levels of ATP
and lactate than mock transfected cells (Figure 4A-B),
which decreased the ATP/AMP ratio in these cells. As
AMP-activated protein kinase (AMPK) acts as a sensor of
cellular energy status and can be activated by a reduction
of ATP/AMP ratio [16], the expression of AMPK and
other proteins involved in the Akt-mTOR pathway were
also examined. The amount of p-AMPK was increased in
the BGC823 cells with pcDNA3.1-FBP2 plasmid. In con-
trast, the amounts of p-Akt and p-S6 were decreased com-
pared with mock transfected cells, although total AMPK,
Akt, and S6 expression remained the same (Figure 4C).
These data indicated that FBP2 overexpression led to
AMPK activation, and thus inhibited Akt-mTOR
signalling.
FBP2 induces apoptosis
Since aerobic glycolysis is a protective strategy against
reactive oxygen species (ROS) [17] and ROS induces
mitochondrial apoptosis [18], the level of intracellular
ROS in BGC823 cells with pcDNA3.1-FBP2 plasmid and
the impact of FBP2-overexpression on apoptosis were
examined. Intracellular ROS in BGC823 cells with
pcDNA3.1-FBP2 plasmid was higher than that in mock
transfected cells (Figure 5A). In addition, annexin V/PI
staining showed that BGC823 cells with pcDNA3.1-FBP2
plasmid had an increased percentage of annexin V+/PI-
and annexin V+/PI+ cells, representing early apoptotic
cells and late apoptotic/necrotic cells [19], respectively,
compared to the mock transfected cells (Figure 5B). Taken
together, these data suggested that FBP2 overexpression
Figure 1 Decreased FBP2 in GC. (A) Glycolysis gene alterations were determined using Oligo gene microarray and high-qualified intestinal-type
GC tissues between GC (20 cases) and paracancerous (20 cases) and normal gastric tissues (5 cases). Columns represent samples and rows
represent genes; red colour represents high expression while green represents low expression. (a) GC versus common reference. (b) Adjacent
normal cancer versus common reference. (c) Normal versus common reference. (B) Levels of FBP2 mRNA expression in GC cell lines BGC823,
MGC803, SGC7901, AGS and N87 by RT-PCR. A pair of GC and adjacent normal tissues was used as controls. (C) Levels of FBP2 protein expression
in GC cell lines BGC823, MGC803, SGC7901, AGS and N87 by Western blot analysis. A pair of GC and adjacent normal tissues was used as controls.
(D) Levels of FBP2 mRNA expression in 16 pairs of GC (T) and adjacent normal tissues (N) were determined by RT-PCR.
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Table 1 Analysis of FBP2 expression in gastric tumours
FBP2 expression
Histology Cases High (%) Low (%) P
Normal 110 63 (57.3) 47 (42.7) < 0.001
Tumour 116 16 (13.8) 100 (86.2)
Bold values indicate P < 0.05.
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compared to mock transfected cells. Protein profiling of
the mitochondrial apoptotic pathway was performed to
gain a deeper understanding of the underlying mechanism
and revealed that the Bax/Bcl-2 ratio was increased and
the activation of their downstream targets, caspase-3 and
caspase-9, were all induced in BGC823 cells with
pcDNA3.1-FBP2 plasmid than mock transfected cells
(Figure 5C).
Hypermethylation of FBP2 promoter reduces the
expression of FBP2 in GC
Methylation status in the genomic FBP2 promoter se-
quence (−2000 to +1000 bp) was investigated using the
free online software, CpG Island Searcher (GC = 55%;
ObsCpG/ExpCpG = 0.65; Length = 200 bp; Gap between
adjacent islands = 100 bp) (Figure 6A). Two CpG
islands FBP2-1 (−1338 to −1014 bp) and FBP2-2 (+29
to +229 bp) were identified and tested for their methyla-
tion status using Sequenom’s MassARRAY system in the
following GC cell lines: BGC823, MGC803, SGC7901,
AGS, and N87. Substantially higher methylation was ob-
served in the FBP2-2 region than in the FBP2-1 region, in-
dicating that the FBP2-2 region may be responsible for
the low FBP2 expression observed in the GC specimens
(Figure 6B). To confirm this finding, the methylation sta-
tus of the FBP2-2 region was determined by bisulphite
genomic sequencing (BGS). The FBP2 promoter was
determined to be heavily methylated in BGC823,Figure 2 Kaplan-Meier plots of univariate analysis of overall survival
(A) For all the patients, (n = 52, P = 0.006). (B) For the patients with poorlyMGC803, SGC7901, AGS and N87 cell lines using this
method (Figure 6C). Importantly, FBP2 expression in
these GC cell lines was substantially restored after
treatment with the demethylating agent, 5-aza-2-
deoxycytidine (5-Aza) (Figure 6D). Furthermore, the
FBP2 promoter was densely methylated in GC tissues
compared to normal gastric tissues (Additional file 2:
Figure S2).
Discussion
In the present study, we showed that decreased expres-
sion of FBP2 gene in GC tissues correlated with poor
patient survival. In addition, tumour depth serves as an
important factor of survival for GC patients which
shown in our observation. This finding indicated that the
metabolic alterations increased the risk of death for GC
patients. Conversely, overexpression of FBP2 suppressed
glucose metabolism, cell proliferation, and induced apop-
tosis. Furthermore, CpG methylation of the FBP2 pro-
moter was correlated with reduction of FBP2 expression,
and FBP2 upregulation inhibited the Akt-mTOR and acti-
vated mitochondrial apoptotic pathways. Taken together,
this inverse correlation between FBP2 expression and cell
proliferation suggested that FBP2 might act as a tumour
suppressor gene in GC.
FBP helps to regulate the level of fructose-1,6-
bisphosphate, one of the most important intermedi-
ates in glycolysis, a major pathway generating ATP
from glucose. Glycolysis metabolises glucose to pyru-
vate, which can then become the precursor of TCA
cycle, the other major pathway directing from glucose
to ATP. FBP converts fructose-1,6-bisphosphate to
fructose-6-phosphate in the reverse direction of gly-
colysis [20]. Recent studies have shown that FBP1
overexpression could suppress glycolysis in cancer
cells [11,12]. Stress that depletes cellular ATP can, in
turn, activate energy sensor AMPK [16]. In our study,of GC patients according to FBP2 expression of their tumours.
differentiated sample, (n = 38, P = 0.042).
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cantly reduced after FBP2 overexpression, while p-AMPK
expression was greatly increased (Figure 4), demonstrating
that FBP2 overexpression suppresses energy production
by aerobic glycolysis and TCA cycle.
In the present study, FBP2 not only suppressed the
glycolysis pathway, but also cell proliferation in GC
(Figure 3). Cancer cells face two major metabolic chal-
lenges: how to meet the bioenergetic and biosynthetic
demands of abnormal proliferation. To overcome these
challenges, cancer cells must reprogram their metabol-
ism and become more dependent on aerobic glycolysis
[6]. This allows the cancer cells to use the most abun-
dant extracellular nutrient, glucose, to produce abun-
dant ATP. Meanwhile, glucose degradation provides
cells with intermediates needed for biosynthetic path-
ways [21]. These observations explain why the suppres-
sion of glycolysis by FBP2 led to inhibition of cell
proliferation in GC cells.
The Akt-mTOR pathway, a master regulator of aerobic
glycolysis and cellular biosynthesis, plays an important
role in satisfying the bioenergetic and biosynthetic needs
of cancer cells [21]. The role of Akt-mTOR in cellular
energy metabolism is coupled to its function in cell pro-
liferation, and mTOR appears to be the most criticaldownstream effector of Akt required for cell proliferation
and tumourigenicity [22]. Conversely, cellular energy sta-
tus affects mTOR activity by the negative regulator AMPK
[23], which at the same time, has an suppressing effect on
Akt activity [24,25]. Thus, FBP2 upregulation in GC cells
suppressed aerobic glycolysis, which in turn, inhibited the
Akt-mTOR pathway by the negative regulator AMPK
(Figure 4), thereby interfering with GC cell proliferation
and tumourigenicity (Figure 3).
Since aerobic glycolysis is a protective strategy against
ROS [17], the suppression of aerobic glycolysis could lead
to an increase in ROS, which has been confirmed to play a
role in the alteration of FBP1 [12]. Here, we showed that
FBP2 overexpression increased ROS (Figure 5). Moreover,
ROS can promote mitochondrial permeabilization and re-
lease of cytochrome c, which can stimulate the caspase
cascade (e.g. caspase-3, caspase-9), with pro-apoptotic
protein Bax and anti-apoptotic protein Bcl-2 as the major
players in these pathways [18]. Thus, upregulation of
FBP2 induced apoptosis in GC cells by increasing the
Bax/Bcl-2 ratio and inducing caspase-3 and caspase-9
activation (Figure 5).
Akt is a major hub of cellular signalling, as its versatile
functions can connect diverse upstream signalling path-
ways to even more diverse physiological outputs, such as
Figure 3 Functional effects of FBP2 on cell proliferation and tumourigenicity. (A) Western blot analysis confirmed FBP2 overexpression in
transfected BGC823 cells. (B) FBP2 overexpression suppressed cell proliferation in the MTT assay (P < 0.05). (C, D) FBP2-overexpressing BGC823
xenografts exhibited decreased tumour size and weight (P < 0.05). (E, F) IHC staining showed FBP2 expression status in tumours (200 ×).
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[26]. In our study, a decrease in Akt could inhibit mTOR
downstream targets, and in turn, cell proliferation. In
contrast, decreased Akt could also enhance caspases ac-
tivation in apoptosis. Therefore, FBP2 overexpression
can simultaneously link Akt to the mTOR and apoptotic
pathways.
Since methylation, one of the major epigenetic modifi-
cations of DNA capable of silencing gene transcription,plays an important role in cancer development [27-29],
and contributes to the Warburg Effect [30], we also de-
termined the methylation status of FBP2 promoter. Our
findings indicated that the FBP2 promoter was highly
methylated in GC (Figure 6), which has been confirmed
in other types of cancer such as brain, liver, breast, and
cervical cancers [31]. Thus, the decrease in FBP2 in GC
might be correlated with promoter methylation and con-
tribute to carcinogenesis in GC.
Figure 4 Functional effects of FBP2 on aerobic glycolysis. (A) Cellular ATP levels measured using a firefly luciferase-based ATP Assay Kit and
normalised to controls showed that FBP2 overexpression inhibited ATP production (P < 0.05). (B) Lactate levels in cellular culture medium
measured using a Lactic Acid Detection Kit and normalised to controls revealed that FBP2 overexpression inhibited lactate production (P < 0.05).
(C) Western blot analysis showed inhibition of the Akt-mTOR pathway in BGC823 cells with pcDNA3.1-FBP2 plasmid compared to mock
transfected cells.
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FBP2 overexpression suppresses glucose metabolism and
inhibits cell proliferation in GC, while reduced FBP2
expression contributes to cancer development. Taken
together, restoration of FBP2 might be a novel and
promising target for cancer therapy.
Methods
Tissue specimens and IHC
Sixteen specimens of primary GC and their paired
noncancerous gastric mucosal tissues were collected from
Beijing Cancer Hospital to determine the level of FBP2
mRNA expression. Another 11 specimens of primary GC
and 6 normal gastric tissues were collected from Beijing
Cancer Hospital to determine the methylation status of
FBP2 promoter. A cohort of 116 formalin-fixed, paraffin-
embedded GC tissues was also obtained from Beijing
Cancer Hospital, in which 52 cases had follow-up data.This study was approved by the Institutional Ethical Stan-
dards Committee with the patients’ written informed con-
sents. The paraffin-embedded microarrays were stained
with rabbit anti-FBP2 antibody (Abcam, Cambridge, MA,
USA). IHC staining was performed using DAB (DAKO,
Carpinteria, CA, USA).Cell culture
Human GC cell lines BGC823, MGC803, and SGC7901
were established in China, and the AGS and N87 cell lines
were purchased from ATCC (Manassas, VA, USA). All
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 5% foetal bovine serum and incubated in a
humidified incubator (5% CO2) at 37°C. For demethyla-
tion treatment, cells were treated with 5 μM 5-Aza
(Sigma-Aldrich, St. Louis, MO, USA) for 72 h. Culture
medium and drugs were replenished every 24 h.
Figure 5 Functional effects of FBP2 on apoptosis. (A) FBP2 overexpression increased intracellular ROS determined using a ROS assay kit
(P < 0.05). (B) AnnexinV/PI staining showed that FBP2 overexpression promoted apoptosis in BGC823 cells (P < 0.05). (C) Western blot analysis
showed the effect of FBP2-upregulation on apoptotic-related genes in BGC823 cells.
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Total RNA was extracted from cell lines and tissues
using a RNApure total RNA isolation kit (Bioteke Cor-
poration, Beijing, China). Reverse transcription reactions
were carried out using EasyScript First-Strand cDNA
Synthesis SuperMix (Transgen Biotech, Beijing, China),
and semi quantitative RT-PCR was performed using 2 ×
Taq PCR Mix (Genstar Biosolutions, Beijing, China).
The primers used for amplification of FBP2 were 5′-
CAGGTTATGCGCTGTACGGT-3′ (Forward) and 5′-
TGATGTAGGCCACGGGATTG-3′ (Reverse). β-actin
was adopted as an internal control in the RT-PCR
reactions.
Sequenom’s MassARRAY EpiTYPER for methylation
analysis
The Sequenom MassARRAY platform (CapitalBio, Beijing,
China) was used for quantitative analysis of FBP2
methylation. This system employs matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
in combination with RNA base-specific cleavage. The
primer pairs for amplifying FBP2-1 (−1338 to −1014 bp)
and FBP2-2 (+29 to +229 bp) regions were 5′-aggaagagagTTTTTGAGATGGAGTTTTATTTTGT-3′
(FBP2-1 Forward) and 5′-cagtaatacgactcactatagggagaaggct
CTCACGCCTATAATCCCAACAC-3′ (FBP2-1 Reverse)
and 5′-aggaagagagGAGATTTTGGTAGGGTTAGTATA
GATT-3′ (FBP2-2 Forward) and 5′-cagtaatacgactcactatag
ggagaaggctAAAACTCACAAATAAACCAAACC-3′ (FBP2-
2 Reverse). Methylation ratios were generated using
EpiTYPER software version 1.0 (Sequenom, San Diego,
CA, USA).
DNA extraction and methylation analysis
Genomic DNA was extracted from cell lines and tissues
using the genomic DNA rapid extraction kit (Aurora
Biomed, Inc., Vancouver, B.C., Canada). Bisulphite modifi-
cation of genomic DNA was performed using Zymo DNA
Methylation Kit (Zymo Research, Irvine, CA, USA). Methy-
lation status of FBP2-2 region was determined by
methylation-specific PCR (MSP) and bisulphite genomic
sequencing (BGS). MSP was carried out for 40 cycles
with annealing temperature at 61°C. Methylation-specific
primers were: MF 5′-ACGGATAGAAGTTTTAGTTC
GAAATC-3′ and MR 5′-AATAAACCAAACCGACCT
TACG -3′, and unmethylation-specific primers were:
Figure 6 (See legend on next page.)
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Figure 6 Decrease FBP2 in GC cells correlated with promoter methylation. (A) Schematic structure of FBP2 CpG islands around exon 1
(+1 to +237). (B) Profiling of site-specific methylation of FBP2 CpG islands: FBP2-1 and FBP2-2 in 5 GC cell lines: BGC823, MGC803, SGC7901, AGS,
and N87. Different colours of circles mark the position of CpG dinucleotides within the sequence (straight line) and the levels of methylation.
Gray circles represent the unanalyzed CpG sites. The “not analyzed” CpG sites have low mass or high mass which cannot be reliably detected.
Data represent at least three independent experiments. (C) Methylation mapping of 13 CpG sites of the FBP2-2 CpG island obtained from BGS in
BGC823, MGC803, SGC7901, AGS, and N87 GC cell lines. White and black circles represent unmethylated and methylated CpG sites, respectively.
(D) Upregulation of FBP2 mRNA expression following treatment with 5-Aza in GC cell lines.
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UR 5′-CAAATAAACCAAACCAACCTTACAC-3′. For
BGS, the following primers were used: BF 5′-
GAGATTTTGGTAGGGTTAGTATAGATT-3′ and BR
5′-AAAACTCACAAATAAACCAAACC-3′. The fragment
amplified corresponded to the FBP2 promoter region, +29
and +229 bp, and the ATG start codon of FBP2 was defined
as +1. PCR products were inserted into pEASY-T1 Cloning
Vector (Transgen Biotech), and at least four colonies were
randomly selected for sequencing.
Ectopic expression of FBP2, cell proliferation and tumour
formation
Full-length FBP2 cDNA was cloned into pcDNA3.1
(Invitrogen, Grand Island, NY, USA) to construct the
transferring plasmid, pcDNA3.1-FBP2. BGC823 cells
were then transfected with either pcDNA3.1-FBP2 or
empty pcDNA3.1 plasmid using the Lipofectamine2000
reagent (Invitrogen) and underwent G418 (400 g/mL)
selection to form stable colonies. Restoration of FBP2
expression was confirmed by Western blot analysis be-
fore these cells were used in any subsequent assays.
Cell proliferation of FBP2-overexpressing BGC823 was
assessed using several different assays. For the MTT
assay, BGC823 cells with pcDNA3.1-FBP2 or empty
pcDNA3.1 plasmid were seeded into 96-well plates, and
absorbance at 570 nm was recorded every 24 h for
5 days. For the soft agar assay, BGC823 cells with
pcDNA3.1-FBP2 or empty pcDNA3.1 plasmid were
suspended in DMEM with 0.3% agarose overlying 0.6%
agarose, and colonies were stained with 0.2% INT after
3–4 weeks of culture.
To determine tumour growth in vivo, approximately
5 × 105 BGC-823 cells with pcDNA3.1-FBP2 or empty
pcDNA3.1 plasmid were injected into female BALB/c
nude mice, which were monitored periodically and
sacrificed 3 weeks later. Tumour specimens from nude
mice were weighed and immunostained. All manipula-
tions involving live mice were approved by the Ethics
Committee of Beijing Cancer Hospital/Institute.
Measurement of ATP and lactate
To measure ATP content and lactate concentration, a
total of 2 × 105 cells per well were seeded into 12-well
plates for 1 day. Cell numbers were determined using aCountess™ automated cell counter (Invitrogen). Medium
was collected to measure lactate levels Nanjing City,
China). Lactate levels were determined by recording the
absorbance at 530 nm using an Ultraspec 3300 Pro (GE
Healthcare Bio-sciences Corp, New Jersey, USA), and
data were normalised to the control group. Trypsin-
dispersed cells were collected to measure the cellular
ATP levels using a firefly luciferase-based ATP Assay Kit
(Beyotime, Haimen City, China). Luminescence in the
ATP assay was measured using an LMax II luminometre
(Molecular Devices, Sunnyvale, CA, USA) and analysed
by SoftMax Pro software Version 5 (Molecular Devices).
Data were normalised to the control group.
Measurement of intracellular ROS and annexin V/PI
staining
Intracellular ROS was examined using a ROS assay kit
(Applygen, Beijing, China), and fluorescence was mea-
sured using a BD FACSAria flow cytometer (BD Biosci-
ences, San Jose, CA, USA) (λex at 488 nm and λem at
520 nm). Apoptosis-mediated cell death was examined
using the Annexin V-FITC Apoptosis Detection Kit
(Beijing Biosea Biotechnology Co. Ltd., Beijing, China).
Cells were detected by flow cytometry (BD FACSAria),
and data were analysed using FASCDiva software. Cells
in early stages of apoptosis were annexin V positive and
PI negative, whereas cells in the late stages of apoptosis
were both annexin V and PI positive.
Western blot analysis
Total proteins were extracted from 5 GC cell lines in
lysis buffer containing 50 mM Tris (pH 6.8), 100 mM
DTT, 1% SDS and 25% glycerol. Equal amount of pro-
teins were electrophoresed on 12% SDS-PAGE and
transferred to PVDF membranes using the Mini PRO-
TEAN 3 system (BIO-RAD, Hercules, CA, USA). PVDF
membranes were blocked in 5% BSA and incubated with
anti-FBP2 (1:1000, Abcam), anti-p-AMPK (1:500, Cell
Signalling Technology, Danvers, MA, USA), anti-AMPK
(1:500, Cell Signalling Technology), anti-p-Akt (1:500,
Cell Signalling Technology), anti-Akt (1:500, Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA), anti-p-S6
(1:500, Epitomics, Burlingame, CA, USA), anti-S6 (1:500,
Cell Signalling Technology), anti-Bcl-2 (1:500, US Bio-
logical, Boston, MA, USA), anti-Bax (1:500, Epitomics),
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or anti-caspase-9 (1:250, Bioworld) antibody, followed by
the appropriate horseradish peroxidase-linked secondary
antibody purchased from Proteintech Group Inc. (Chicago,
IL, USA). Anti-β-actin (1:10000, Sigma) antibody was used
to detect the loading control.
Statistical analysis
All statistical analyses were performed using SPSS 13.0
software. Student’s t test was used to compare groups in
the MTT and soft agar assays. Student’s t test was also
used to determine remarkable differences between groups
regarding tumour size and weight, ATP content and lac-
tate concentration, ROS and apoptotic rate. The χ2 and
Fisher’s exact test were used to determine the difference
of FBP2 protein expression levels between GC and adja-
cent normal tissues. The Kaplan-Meier method was used
for plotting survival curves, and survival data were evalu-
ated using multivariate Cox regression analysis. For all
analyses, data were shown as mean ± SD, and P < 0.05 was
considered statistically significant.
Additional files
Additional file 1: Figure S1. Representative immunohistochemical
staining of FBP2 in tissue microarrays (original magnification × 200).
(A) Normal gastric tissue. (B) The cervical part of normal gastric tissue.
(C) Well/moderately differentiated GC tissue with high FBP2 expression.
(D) Well/moderately differentiated GC tissue with low FBP2 expression.
(E) Poorly differentiated GC tissue with high FBP2 expression. (F) Poorly
differentiated GC tissue with low FBP2 expression. (G) A transition
staining of FBP2 from GC to adjacent normal tissue.
Additional file 2: Figure S2. The methylation status of FBP2 promoter
was determined by MSP and USP (unmethylation-specific PCR) in GC (T)
and normal gastric tissues (N). Primer efficiency was verified by positive
control (in vitro methylated DNA, IVD) and negative control (normal
lymphocyte DNA, NL). ddH2O, double-distilled water, was used as blank
control. M, methylated alleles; U, unmethylated alleles.
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